Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.

ABSTRACT: In pandemic scenarios involving novel human pathogenic viruses, it is highly desirable that vaccines induce strong neutralizing antibodies as quickly as possible. However, current vaccine strategies require multiple immunization doses to produce high titers of neutralizing antibodies and are poorly protective after a single vaccination. We therefore wished to design a vaccine candidate that would induce increased protective immune responses following the first vaccine dose. We hypothesized that antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein could be increased by drawing upon immunity to a previous infection. We generated a fusion protein containing the influenza H1N1 PR8 virus nucleoprotein (NP) an

SUBMITTER: Dulin H 

PROVIDER: S-EPMC10878257 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature